Press Release: Sanofi successfully prices 2.3 billion of bond issue

Press Release

Sanofi successfully prices 2.3 billion of bond issue

Paris, April 24, 2026 - Sanofi announces that it has successfully priced its offering of €2.3 billion of notes across 3 tranches:

• €1,000 million fixed-rate notes, due May 2029, bearing interest at an annual rate of 3.000%
• €650 million fixed-rate notes, due May 2033, bearing interest at an annual rate of 3.375%
• €650 million fixed-rate notes, due May 2037, bearing interest at an annual rate of 3.750%

The notes are being issued under Sanofi's Euro Medium Term Note programme.

Sanofi intends to use the net proceeds of the offering for general corporate purposes.

The transaction has been led by Citigroup, HSBC, and J.P. Morgan as global coordinators, and Credit Agricole CIB, Deutsche Bank, RBC Capital Markets, and Unicredit, all as joint lead managers.

About Sanofi

Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations

Sandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com

Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com

Léo Le Bourhis | + 33 6 75 06 43 81 | leo.lebourhis@sanofi.com

Victor Rouault | + 1 617 356 4751 | victor.rouault@sanofi.com

Timothy Gilbert | + 1 516 521 2929 | timothy.gilbert@sanofi.com

Léa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com

Ekaterina Pesheva | +1 420 926 6780 | ekaterina.pesheva@sanofi.com

Investor Relations

Thomas Kudsk Larsen | + 44 7545 513 693 | thomas.larsen@sanofi.com

Alizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com

Keita Browne | + 1 781 249 1766 | keita.browne@sanofi.com

Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com

Nina Goworek | + 1 908 569 7086 | nina.goworek@sanofi.com

Thibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com

Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com

Disclaimer

This communication shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This is neither an advertisement and not a prospectus for the purposes of Regulation (EU) 2017/1129 of June 14, 2017 (as amended, the “Prospectus Regulation”), nor a prospectus within the meaning of the Public Offers and Admissions to Trading Regulations 2024, and has not been approved, filed, or reviewed by any regulatory authority of the EEA or the United Kingdom.

The Notes have not been and will not be registered under the Securities Act and may not be offered or sold within